Occlutech AFR Heart Failure Device Obtains CE Mark Approval

Food and Healthcare Press Releases Monday September 9, 2019 09:23
SCHAFFHAUSEN, Switzerland--9 Sep--PRNewswire/InfoQuest

Occlutech AG announced today that its atrial flow regulator, the Occlutech AFR device, has obtained CE mark approval clearing it for sales on the European CE regulated market. Occlutech AFR is a next generation intra-atrial shunt device, intended to treat heart failure symptoms by decompressing abnormal intra-atrial pressure. It is placed in the septum between the left atrium and right atrium in a minimally invasive procedure. It is manufactured in different sizes thereby allowing unique patient-oriented and individualized treatment.

In Europe and around the world, millions of patients suffer from heart failure and several hundred thousand die from this condition every year. Many of these patients suffer from decreasing cardiac output that originates from a malfunction of the left heart. As a consequence, the left atrium will dilate and become volume and pressure overloaded. This leads to the most important clinical symptom of heart failure, i.e. pulmonary congestion and shortness of breath. By placing the Occlutech AFR device into the septum and creating a restrictive atrial septal opening by maintaining the correct sizing of a created shunt, the intra cardiac pressure is substantially reduced, thereby improving the heart's function.

"With CE mark approval of the Occlutech AFR we are taking another big step towards becoming a multi-franchise congenital and structural heart disease therapy provider." says Sabine Bois, Co-CEO of Occlutech AG. Additionally, she states that "the Occlutech AFR with its efficacy, versatility, convenience and safety has true potential to revolutionize the way heart failure patients are treated."

Occlutech is one of the leading companies in its field, with several major products including state-of-the-art PFO occluders, ASD occluders among others. Occlutech has sales of congenital and structural heart products in over 80 countries and maintains manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey. Occlutech has developed many novel products and technologies to improve treatment of patients in these and related areas. (www.occlutech.com)

Contact:
Sabine Bois
Co-CEO Occlutech Group
Mobile: +49-160-90792130
Email: sabine.bois@occlutech.com
Susanne Goransson
Executive Assistant
Mobile: +46-704-33-65-21
Email: susanne.goransson@occlutech.com
Logo - https://mma.prnewswire.com/media/971275/Occlutech_International_AB_Logo.jpg

Latest Press Release

Califia Farms Completes Landmark $225 Million Financing with Diverse Group of Global Investors

Funding Provides Califia Farms, a leading plant-based food and beverage company, with long-term capital and global support for continued rapid expansion, and disruption of the $1 trillion+ dairy and ready-to-drink coffee markets Califia Farms(R), a...

Herbalife Nutrition Expert Shares Valuable Nutrition Tips to Make Smart Food Choices and Promote Healthy Eating Habits

Herbalife Nutrition (NYSE:HLF), a premier global nutrition company, recently invited Dr.Jonathan Yarom, Herbalife Nutrition Advisory Board Member, to share valuable health and nutrition information to its Independent Members in Thailand. Dr. Yarom has...

Jetts 24 Hour Fitness registers record-breaking growth in Asian fitness industry with opening of 22 clubs across Thailand in 24 months

Jetts 24 Hour Fitness, the fastest-growing fitness chain in Thailand, now has a total of 22 clubs up and running in the country in a testament to its philosophy of bringing exercise opportunities to people with the utmost ease of convenience. Thailand's...

12th Consecutive Year Leading United States in Organ Donation for Gift of Life Donor Program

Region Again Breaks Two U.S. Records, Showing Extraordinary Generosity and Clinical Leadership: Most Organ Donors and Life-Saving Transplants For the 12th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement...

CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs

CF PharmTech, Inc., a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $90 million Series E investment led by New Alliance Capital. The investment included participation...

Related Topics